It is made available under a CC-BY-NC-ND 4.0 International license .

1 Title: The estimated disease burden of COVID-19 in Japan from 2020 to 2021

2 Running title: Disease burden of COVID-19 in Japan, 2020-2021

- 3
- 4 Shinya Tsuzuki, MD, $MSc^{1,2,3*}$; Philippe Beutels, PhD^2
- ⁵ ¹ Disease Control and Prevention Center, National Center for Global Health and
- 6 Medicine, Tokyo, Japan
- ⁷ ² Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- ⁸ ³ AMR Clinical Reference Center, National Center for Global Health and Medicine,
- 9 Tokyo, Japan
- 10
- 11 *Corresponding author: Shinya Tsuzuki, MD, MSc
- 12 National Center for Global Health and Medicine
- 13 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
- 14 Tel: +81(0)3-3202-7181
- 15 Email: <u>stsuzuki@hosp.ncgm.go.jp</u>
- 16

It is made available under a CC-BY-NC-ND 4.0 International license .

17 Abstract

- 18 **Background:** To date, it is not fully understood to what extent COVID-19 has burdened
- 19 society in Japan. This study aimed to estimate the total disease burden due to COVID-
- 20 **19 in Japan during 2020-2021**.
- 21 **Methods:** We stratify disease burden estimates by age group and present it as absolute
- 22 Quality Adjusted Life Years (QALYs) lost and QALYs lost per 100,000 persons. The
- total estimated value of QALYs lost consists of (1) QALYs lost brought by deaths due
- to COVID-19, (2) QALYs lost brought by inpatient cases, (3) QALYs lost brought by
- ²⁵ outpatient cases, and (4) QALYs lost brought by long-COVID.
- ²⁶ Findings: QALYs lost due to COVID-19 was estimated as 286,781.7 for two years,
- 114.0 QALYs per 100,000 population per year. 71.3% of them were explained by the
- ²⁸ burden derived from deaths. Probabilistic sensitivity analysis showed that the burden of
- 29 outpatient cases was the most sensitive factor.

30 Interpretation: The large part of disease burden due to COVID-19 in Japan from the

- beginning of 2020 to the end of 2021 was derived from Wave 3, 4, and 5 and the
- 32 proportion of QALYs lost due to morbidity in the total burden increased gradually. The
- 33 estimated disease burden was smaller than that in other high-income countries. It will be
- ³⁴ our future challenge to take other indirect factors into consideration.

- ³⁵ **Fundings:** This research was funded by JSPS KAKENHI [Grant number 20K10546].
- ³⁶ The funders had no role in study design, data collection and analysis, decision to
- 37 publish, or preparation of the manuscript.
- 38
- 39 Keywords: COVID-19; disease burden; Japan
- 40 Word count: 3,588

It is made available under a CC-BY-NC-ND 4.0 International license .

41 Acknowledgment

42 Not Applicable.

43

44 Author contributions

- 45 Shinya Tsuzuki: Conceptualization, Funding Acquisition, Data Curation, Formal
- 46 Analysis, Methodology, Visualization, Original Draft Preparation. Philippe Beutels:
- 47 Supervision, Project Administration, Review & Editing.

48

49 Data availability

50 The data that support the findings of this study are freely available through online.

51

52

53 Conflict of interest

- 54 ST reports payment for supervising medical articles outside this study from Gilead
- 55 Sciences, Inc. PB reports grants from Pfizer, GlaxoSmithKline, and the European
- 56 Commission IMI, unrelated to this work.

57

58 **Ethics approval**

- 59 This study analysed data which were publicly available. As such, the datasets used in
- 60 our study were de-identified and fully anonymized in advance, then therefore this this
- 61 study did not require ethical approval.
- 62
- 63
- 64

It is made available under a CC-BY-NC-ND 4.0 International license .

65 Introduction

66	Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus, has become a
67	global health threat since the beginning of 2020^{1-3} . In Japan, it was first detected in
68	early 2020 ⁴ .
69	This emerging infectious disease became one of the most pressing concerns for
70	the Japanese general population and the Ministry of Health, Labour and Welfare
71	(MHLW) Japan in early 2020 and the Prime Minister of Japan declared the state of
72	emergency on 7 th April 2020 for seven prefectures including the Tokyo metropolitan
73	area ⁵⁻⁷ . MHLW recommended to avoid Three Cs (Closed spaces, Crowded places, and
74	Close-contact settings) to prevent COVID-19 transmission ⁸ and behaviour of the
75	general population drastically changed. The number of healthcare facility visits and the
76	consumption of antimicrobials decreased substantially after the emergence of COVID-
77	19 in Japan ^{9,10} . In short, the COVID-19 pandemic changed the Japanese
78	way of life substantially.
79	To date, it is not fully understood to what extent this novel emerging disease
80	has burdened society. A quantification of the observed burden, despite the great efforts
81	that were made to minimise it, is a first step towards understanding how pandemic
82	management can be improved.
83	Compared with other high-income countries, the cumulative incidence of

It is made available under a CC-BY-NC-ND 4.0 International license .

84	COVID-19 cases, hospitalisations and deaths has been comparatively small in Japan, at
85	least until the end of the year 2021^{11} . For instance, the United Kingdom reported 952.6
86	cumulative hospitalizations per 100,000 population ¹² and the United States reported
87	11,700.6 cumulative hospitalizations per 100,000 population at the end of 2021^{13} , while
88	Japan reported 1,706.1 cumulative hospitalizations per 100,000 population in the same
89	period. As for deaths, Japan reported lower rates (14.6 deaths per 100,000 population)
90	compared with the UK and the US (218.1 and 247.8 deaths per 100,000 population,
91	respectively) and the average of the world $(69.1 \text{ deaths per } 100,000 \text{ population})^{14}$.
92	In order to learn from the crisis and be better prepared for future pandemics, we
93	aim to assess the burden caused by COVID-19 in more detail. We can classify the
94	disease burden directly caused by COVID-19 into four categories;
95	
96	(i) Quality Adjusted Life Year (QALY) losses caused by fatal cases
97	(ii) QALY losses caused by outpatient cases
98	(iii) QALY losses caused by mild to severe inpatient cases
99	(iv) QALY losses caused by long-COVID ¹⁵
100	

101 Since they can be both interpreted as indicators of pandemic management, here we aim

It is made available under a CC-BY-NC-ND 4.0 International license .

102 to document both	the cumulative and the	e chronological, per	-wave, disease burden
----------------------	------------------------	----------------------	-----------------------

- 103 caused by COVID-19. The COVID-19 epidemic in Japan was characterised by five
- 104 waves in 2020 and 2021. We adopted a previously proposed classification of waves
- 105 observed in Japan¹⁶, as follows (see also Figure 2):

- 107 (i) First wave (Wave 1), 01/01/2020-05/31/2020;
- 108 (ii) Second wave (Wave 2), 06/01/2020-10/31/2020;
- 109 (iii) Third wave (Wave 3), 11/01/2020-03/31/2021;
- 110 (iv) Fourth wave (Wave 4), 4/1/2021-6/30/2021;
- 111 (v) Fifth wave (Wave 5), 7/1/2021-12/31/2021
- 112
- 113 The Japanese government had implemented different non-pharmaceutical interventions
- 114 (NPIs) in each period and the guidelines for clinical management of COVID-19 cases
- grew gradually, implying the characteristics of the burden in each wave are expected to
- 116 be different.
- 117 The main objective of this study is to assess the disease burden caused by
- 118 COVID-19 in Japan between the beginning of 2020 and the end of 2021 in order to
- 119 enable comparisons over time, with other diseases and with other countries.

It is made available under a CC-BY-NC-ND 4.0 International license .

120

121 Methods

122 Settings

123	We constructed a progression pathway model of COVID-19 infection (Figure 1), in
124	which two types of infection; symptomatic and asymptomatic, and three degrees of
125	severity were defined; outpatient cases, inpatient cases (mild), and inpatient cases
126	(severe). The definition of "severe" inpatient cases varied by prefecture because each
127	prefecture defined the severity of inpatient COVID-19 cases by its own criteria. A large
128	part of prefectures defined "severe" cases as patients admitted to an intensive care unit
129	(ICU) or patients requiring mechanical ventilation. Additionally, we assumed that any
130	type of symptomatic infection could lead to long-COVID. In line with previous
131	studies ^{17,18} , we defined long-COVID patients as presenting with COVID-19 symptoms
132	for longer than four weeks from symptom onset. The final stage of each infected case
133	was "Death" or "Recovery". We assumed that all symptomatic infections (both
134	outpatient and inpatient cases), including long-COVID episodes, and deaths contributed
135	to the disease burden, whereas asymptomatic infections did not.

136

137 (Figure 1)

It is made available under a CC-BY-NC-ND 4.0 International license .

138

139	We estimated the disease burden due to COVID-19 in Japan for the period
140	from the beginning of 2020 to the end of 2021 because the first case of COVID-19 in
141	Japan was detected on 15^{th} January 2020 ⁴ , and by the end of 2021 80.4% of the
142	population had received their primary course of COVID-19 vaccination. Additionally,
143	the less severe Omicron variant of concern (VOC), became dominant early in 2022, and
144	its clinical, detection and epidemiological characteristics were quite different from other
145	strains.
146	
147	Data sources
148	We used open data sources for the daily number of confirmed cases and deaths ^{19} .
149	Demographic data were sourced from official statistics ²⁰ . Disutility of each health status
149 150	Demographic data were sourced from official statistics ²⁰ . Disutility of each health status was presented as QALYs lost per episode and defined according to values from the
149 150 151	Demographic data were sourced from official statistics ²⁰ . Disutility of each health status was presented as QALYs lost per episode and defined according to values from the literature ^{17,21,22} . We assumed the proportion of acute symptomatic COVID-19 cases that

153 of these parameters is shown in Table 1.

154

It is made available under a CC-BY-NC-ND 4.0 International license .

156

157 **Table 1. Details of parameters included in the model**

Parameters	Value	Distribution	Reference
Disutility (QALYs lost)			
Outpatient case	0.033	Lognormal	21
		(mean = -5.187, SD = 0.034)	
Innotiont case	0.430	Normal	22
inpatient case	0.439	(mean = 0.439, SD = 0.027)	
Long-COVID	0.129	Lognormal	17
		(mean = -4.209, SD = 2.597)	
Proportion with long-COVID			
In adults	0.166	Binomial	23
In children (under 20)	0.039	Binomial	24

158

159

160 Estimation of disease burden

161 We stratify the disease burden estimates by age group and present it as absolute QALYs

162 lost^{25,26} and QALYs lost per 100,000 persons.

163

164	QALYs lost due to premature mortality were calculated as the remaining life
165	expectancy at the time of death per fatal case, i.e., the number of life years lost (LYL).

166 We used nine age groups, in accordance with available Covid-19 mortality statistics: <

167 10 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years,

168	70-79 years, 80-89 years, and \geq 90 years, and assumed deaths reported within a given
169	age group occurred at the mid-point of the age interval, in line with previous studies ^{27,28} .
170	QALYs lost due to inpatient cases were calculated by multiplying the total
171	number of mild/severe inpatient cases with the disutility per COVID-19 inpatient case.
172	Similarly, QALYs lost due to outpatient and long-COVID cases were calculated by
173	multiplying the total number of outpatient and long-COVID cases with the respective
174	disutilities per case (see table 1).
175	The total disease burden of COVID-19 was expressed as the sum of the above,
176	i.e., the QALYs lost due to disease in inpatient cases, outpatient cases and due to
177	premature deaths.
178	Two-sided p values of < 0.05 were considered to show statistical significance.
179	All analyses were conducted by R, version $4.1.3^{29}$.
180	
181	Sensitivity analysis
182	We conducted probabilistic sensitivity analysis to acknowledge uncertainty and examine
183	the robustness of our results. We ran 1,000 simulations of the disease burden estimation
184	with different sets of parameter values derived from the defined ranges and distributions.
185	The range of each parameter, distribution, and the references we used to determine it are

It is made available under a CC-BY-NC-ND 4.0 International license .

available in Table 1. The influence of each parameter on the	total disease burden was
--	--------------------------

- 187 evaluated by a linear regression analysis with 1,000 simulation results as an independent
- variable and 1,000 parameter sets as dependent variables.

189

190

191 Ethics approval

All data used in this study are publicly available. As such, the datasets used in our study

193 were de-identified and fully anonymized. Therefore, this study did not require specific

194 ethical approval.

195

196

197 **Results**

198	In total, 1,728,228 COVID-19 cases were confirmed in Japan from the beginning of
199	2020 to the end of 2021. Among them, 232,495 cases were observed in 2020 and
200	1,495,733 cases in 2021. A relatively small number of cases was observed in Waves 1
201	and 2 (99,959 cases and 1,765 deaths) in Japan, and more than half of the total cases
202	between 2020 and 2021 were observed in Wave 5 (931,393 cases), although the number
203	of deaths in Wave 5 was comparatively small (3,762 deaths). Similarly, the maximum

204	number of cases requiring hospitalization in Wave 1 was 6,250, while in Wave 5 it was
205	231,596. Figure 2 shows the epidemic curve of confirmed cases and number of cases
206	requiring hospitalization from 2020 to 2021. When the life years lost were adjusted by
207	the age-specific population norm for health-related quality of life (as shown in the
208	Supplementary file), the interpretation of these results did not change.
209	
210	(Figure 2)
211	
212	More than a half of total cases were observed in Wave 5 (931,393 cases). The
213	Delta variant of concern (VOC) was dominant in this period ^{30,31} , as it outcompeted the
214	less transmissible Alpha VOC in July 2021.
215	The number of fatal cases was 3,095 in 2020 and 14,520 in 2021. The case-
216	fatality ratio (CFR) was 0.013 in 2020 and 0.0097 in 2021, respectively. The estimated
217	average age of fatal cases was 80.2 (Wave 1 and 2), 82.3 (Wave 3), 81.5 (Wave 4), and
218	75.8 (Wave 5) years.
219	
220	QALYs lost due to COVID-19 were estimated as 286,781 over two years, or an
221	average of 114.0 QALYs per 100,000 population per year. The observed disease burden

It is made available under a CC-BY-NC-ND 4.0 International license .

222	differed substantially between waves: from 8.5 QALYs per 100,000 population in Wave
223	1, up to 96.2 QALYs per 100,000 population in Wave 5. Figure 3 shows the evolution of
224	QALYs lost per 100,000 population in the total population and by broad age group
225	(under 40, 40-69, and over 69) over the waves. The disease burden in younger age
226	groups gradually increased during the study period with 36.4%, 47.6%, 36.6%, 45.0%
227	and 68.2% of the QALYs lost occurring in the age groups younger than 70 in Waves 1
228	through 5, respectively. When life years lost are adjusted for quality these percentages
229	become38.7%, 50.7%, 39.6%, 48.3%, and 70.7%, respectively.
230	
231	(Figure 3)

232

233	More than 70% of QALYs were lost due to premature mortality (204,437.2 out
234	of 286,781.7, 71.3%), while nearly 20% were lost due to morbidity in outpatient cases
235	(57031.5 QALYs lost, 19.9%), and only a small part of the burden came from morbidity
236	in severe cases (422.5 QALYs lost, 0.1%). Long-COVID accounts for 3.4% of the total
237	disease burden (9,791.7 QALYs lost). Figure 4 shows the breakdown of disease burden
238	attributed to each clinical status.

239

It is made available under a CC-BY-NC-ND 4.0 International license .

240 (Figure 4)

241

242	Probabilistic sensitivity analysis showed the disease burden directly due to
243	COVID-19 ranged between 226,883 and 512,236 (median 242,834, IQR 236,108 to
244	254,488) QALYs, or between 90.1 and 203.6 (median 96.5, IQR 93.8 to 101.1) QALYs
245	per 100,000 population. The disutility per outpatient case was the most influential
246	parameter for the estimated QALY losses due to morbidity, whereas the disutility per
247	long-COVID patient was the second most influential. Figure 5 shows the influence of
248	these and the other input parameters by their coefficient in a linear regression analysis
249	using 1,000 input parameter sets and 1,000 associated QALY estimates. Clearly,
250	accurate estimates for the disutilities per outpatient and per long-COVID patient are
251	important to estimate the burden of disease from COVID-19.
252	

253 (Figure 5)

254

255 **Discussion**

To the best of our knowledge, this is the first study which estimated the disease burden directly due to COVID-19 in Japan in the first two years of the pandemic. The

It is made available under a CC-BY-NC-ND 4.0 International license .

258	disease burden brought by this emerging infectious disease during the first two years
259	was smaller than in most other high-income countries (HICs). For instance, McDonald
260	and colleagues reported that the total disease burden per-capita in the Netherlands in
261	2020 due to COVID-19 was 1,640 Disability-adjusted life-years (DALYs) per 100,000
262	population ³² . This number is more than ten times higher than that of our study. Other
263	countries, e.g., Scotland and Malta, also reported similar size of burden in 2020 ^{33,34} .
264	Germany and Denmark reported smaller burden, however, the results were still much
265	larger than ours (368 and 520 DALYs/100,000, respectively) ^{35,36} .
266	An obvious difference between previous studies and ours is that we used QALYs
267	instead of DALYs to express burden of disease. Many guidelines advocate the use of a
268	combined measure of morbidity and mortality as preferred outcome in economic
269	evaluation, and the majority of country-specific guidelines, including those for Japan,
270	prescribe the use of QALYs ³⁷ , although some influential generic guidelines such as the
271	IDSI ³⁸ and the 2019 WHO guide for economic evaluation of vaccinations ³⁹ indicate that
272	the choice between these outcome measures may depend on the analyst's preference and
273	of the specific intervention under study. QALYs were used in our study to include the
274	disease burden attributable to long-COVID based on a previous observational Japanese

study using the EQ-5D-3L questionnaire¹⁷. Although this choice may limit the

276	comparability with studies using DALYs as an outcome, it allows us to attain our
277	primary objective, i.e., assessing the disease burden by clinical manifestation, wave and
278	age group, and have a basis to start from to assess the QALY impact of interventions (as
279	one would for economic evaluation). Furthermore, DALYs were conceived in a very
280	similar manner as QALYs, and applied studies using both measures have reported
281	relatively small differences ²⁵ .
282	As for the total disease burden, this could be simply attributed to the relatively small
283	number of confirmed cases and deaths per population in Japan ¹¹ . Mortality of COVID-
284	19 cases was smaller in Japan than in most other HICs during the study period ^{19,40-42} .
285	With regard to the number of deaths, the total number of all-cause excess deaths from
286	the beginning of 2020 to the end of 2021 was estimated at between 11,014 and 58,905,
287	while all-cause exiguous deaths in the same period was between $9,069$ and $45,185^{43}$.
288	Considering these numbers included the influence of diseases other than COVID-19, the
289	number of indirect deaths due to COVID-19 might not change the total burden estimates
290	substantially. One can speculate about the reasons why the COVID-19 case and death
291	toll tended to be lower in Japan than in many other HICs. Basically, people who
292	presented fever or any symptoms suspicious of COVID-19 were required to visit one of
293	the designated medical facilities and physicians who diagnosed COVID-19 had to report

It is made available under a CC-BY-NC-ND 4.0 International license .

all COVID-19 cases they diagnosed, implying the potential risk of underestimating the number of cases was low. The cumulative number of COVID-19 cases in Japan increased most steeply after the emergence of the Omicron VOC, and the proportion of the Japanese population with non-vaccine induced immunity against COVID-19 remained low, even in 2021⁴⁴.

299 Considering the breakdown of QALYs lost, the part of the burden attributable to 300 fatal cases was smaller than that in previous studies. Although only 71.3% of QALYs 301 lost was attributed to fatal cases in our study, more than 90% of the total burden was attributed to LYL in previous studies in other countries^{32–36}. It may be partly explained 302 303 by some studies not including the burden of long-COVID. Furthermore, we have used a 304 simplified approach by counting each lost life year as one, implying that each of these 305 life years was assumed to be lived in perfect health. We also made estimates accounting 306 for a quality adjustment in the life years gained, and as expected, this leads to lower estimates of the QALYs lost due to premature mortality. 307

The probabilistic sensitivity analysis acknowledges parametric uncertainty and indicates a relatively wide range for the total disease burden. This might be attributed to uncertainty in the estimation of the burden of outpatient cases and long-COVID because we defined the range of disease burden caused by these two statuses according to

312	empirical data in our previous studies ^{17,21} , then small sample sizes affected their
313	uncertainty. Additionally, it would also be due to the fact that there is no single
314	established definition of long-COVID. Tsuzuki et al defined long-COVID as four weeks
315	or longer duration of symptoms after diagnosis of COVID-19 ¹⁷ , however, WHO defines
316	post COVID-19 condition as the status "usually 3 months from the onset of COVID-19
317	with symptoms and that last for at least 2 months and cannot be explained by an
318	alternative diagnosis ⁷⁴⁵ . With changing definitions, the proportion of symptomatic cases
319	incurring long-COVID varies significantly. In addition, disutility of each long-COVID
320	case varies substantially by study ^{46–48} which will bring further uncertainty.
321	There are several limitations in this study, similar to the previous studies. First, our
322	results did not consider how many cases were unreported. As described above, all
323	diagnosed COVID-19 cases including asymptomatic ones had to be reported in Japan,
324	nevertheless some level of underreporting seems inevitable. For instance, McKenzie and
325	colleagues insisted that there might be 1.77 times higher number of cases than reported
326	during the same period (from the beginning of 2020 to the end of 2021) ⁴⁹ . It is difficult
327	for us to estimate the precise cumulative incidence of COVID-19 because we have very
328	little evidence on the seroprevalence of SARS-CoV-2 in Japan ^{44,49} . However, most of
220	such unreported cases were expected to be "asymptomatic" because they had to be

It is made available under a CC-BY-NC-ND 4.0 International license .

330	reported if they presented any suspicious symptoms. Since our objective is to assess the
331	disease burden directly attributable due to COVID-19, we can ignore such cases,
332	although they may have given rise to anxiety, especially in 2020, and have an impact on
333	mental wellbeing in both the infected person and their direct contacts in and outside the
334	household.

335 Second, we did not take the burden to the healthcare systems into consideration. Japanese government decided to admit all the patients diagnosed with COVID-19 336 regardless of its severity in the early phase of the pandemic⁵. As a result, a large number 337 of tertiary hospitals could not offer normal healthcare due to high burden of the 338 management of COVID-19 cases. This would have brought additional burden to society 339 as previous studies reported^{50,51}. Nevertheless, we believe that this additional burden to 340341 the healthcare system did not contribute to increase the total disease burden, because 342 excess mortality attributable to the causes other than COVID-19 was smaller than before during the study period⁴³, and no large catch-up effect due to postponed care has 343 344 been detected in mortality statistics to date.

Third, we could not consider the impact of non-pharmaceutical interventions (NPIs). The Japanese government had implemented a "state of emergency" declaration as a kind of recommendation to avoid social contact like capital lockdown in other countries⁵².

348	Such interventions might contribute to decrease the number of COVID-19 cases in
349	exchange for the economic burden. We have scarce evidence about both the economic
350	aspects of these non-pharmaceutical countermeasures so far and a counterfactual
351	scenario about the burden of disease and the economic impact in case we had not
352	implemented such NPIs. Although it seems clear that the total disease burden due to
353	COVID-19 in Japan was relatively smaller than in most other HICs, the impact of the
354	indirect effects of NPIs on the overall disease burden remains a topic on research, as it
355	is in many other countries.
356	Fourth, we did not distinguish between primary and secondary infections in
357	unvaccinated persons and breakthrough infections in vaccinated persons. The cases
358	reported in 2021, included breakthrough infections, but we lacked the information to
359	specify these cases. Al-Aly et al. showed that the risk of death and post-acute sequelae
360	were higher in unvaccinated cases than breakthrough infections ⁵³ , and the total burden
0.01	

- Nevertheless, the number of breakthrough infection can be considered smaller than the
 normal ones, then its impact also should be a small one.
- Fifth, in line with all other studies known to us, we exclude other indirect aspects of the disease burden such as that caused by isolation, imposed on patients' family

It is made available under a CC-BY-NC-ND 4.0 International license .

members, and so forth, because the number of isolated persons and the number of

366

367	patients' household members are not well documented. Although our previous studies
368	had estimated the per-patient impact of these aspects ^{21,54} , future work will attempt to
369	combine these results with the estimated number of isolated people and household
370	members of infected cases as part of a more general assessment of the indirect burden.
371	
372	Conclusions
373	Most of the disease burden due to COVID-19 in Japan from the beginning of 2020 to
374	the end of 2021 was incurred in 2021 during waves 3, 4, and 5. The proportion of the
375	total burden due to non-fatal disease increased gradually and this was probably due to
376	the lower mortality by COVID-19 in the latter half of the study period, especially in the
377	elderly. It also shows that younger people contributed more to the disease burden as
378	SARS-CoV-2 circulated more in the general population from 2021 onwards. The
379	estimated disease burden in Japan was smaller than in most other HICs and this can be
380	attributed to the small number of confirmed cases in Japan. Future research may further
381	explore the underlying reasons for the lower cumulative incidence of COVID-19 cases
382	in Japan, while taking contextual factors into consideration.
383	

It is made available under a CC-BY-NC-ND 4.0 International license .

386		References						
387 388	1	Guan W, Ni Z, Hu Y, <i>et al.</i> Clinical Characteristics of Coronavirus Disease 2019 in China. <i>N Engl J Med</i> 2020; 382 : 1708-20.						
389 390	2	Huang C, Wang Y, Li X, <i>et al.</i> Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. <i>The Lancet</i> 2020; 395 : 497-506.						
391 392 393	3	Chen N, Zhou M, Dong X, <i>et al.</i> Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. <i>The Lancet</i> 2020; 395 : 507-13.						
394 395 396	4	Ministry of Health, Labour and Welfare. Current status of the novel coronavirus infection and the response of the MHLW. https://www.mhlw.go.jp/stf/newpage_09290.html (accessed June 1, 2022).						
397 398 399 400	5	Ministry of Health, Labour and Welfare. Information list for local authorities and healthcare facilities: COVID-19. 2020. https://www.mhlw.go.jp/stf/seisakunitsuite/newpage_00024.html (accessed Aug 17, 2021).						
401 402 403	6	Matsunaga N, Hayakawa K, Terada M, <i>et al.</i> Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. <i>Clin Infect Dis</i> 2020; published online Sept. DOI:10.1093/cid/ciaa1470.						
404 405	7	Inoue H. Japanese strategy to COVID-19: How does it work? <i>Global Health & Medicine</i> 2020; 2 : 131-2.						
406 407 408	8	Ministry of Health, Labour and Welfare. Information on health and medical consultation. https://www.mhlw.go.jp/stf/covid-19/kenkou-iryousoudan_00006.html (accessed Feb 23, 2022).						
409 410 411	9	Yamaguchi S, Okada A, Sunaga S, <i>et al.</i> Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. <i>BMJ Open</i> 2022; 12 : e060390.						
412	10	Ono A, Koizumi R, Tsuzuki S, <i>et al.</i> Antimicrobial Use Fell Substantially in						

It is made available under a CC-BY-NC-ND 4.0 International license .

- Japan in 2020-The COVID-19 Pandemic May Have Played a Role. International
 Journal of Infectious Diseases 2022. DOI:10.1016/j.ijid.2022.03.019.
- 41511 Coronavirus(COVID-19)Cases-OurWorldinData.416https://ourworldindata.org/covid-cases(accessed Feb 24, 2022).
- 417 12 Healthcare in the UK | Coronavirus in the UK.
 418 https://coronavirus.data.gov.uk/details/healthcare (accessed Dec 3, 2022).
- 419 13 United States COVID-19 Overview Johns Hopkins. Johns Hopkins Coronavirus
 420 Resource Center. https://coronavirus.jhu.edu/region/united-states (accessed
 421 Dec 3, 2022).
- 422 14 Idogawa M, Tange S, Nakase H, Tokino T. Interactive Web-based Graphs of
 423 Coronavirus Disease 2019 Cases and Deaths per Population by Country. *Clinical*424 *Infectious Diseases* 2020; 71: 902-3.
- 425 15 del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19.
 426 JAMA 2020; published online Oct 5. DOI:10.1001/jama.2020.19719.
- 427 16 Hayakawa K, Asai Y, Matsunaga N, *et al.* Evaluation of the representativeness
 428 of data in the COVID-19 Registry Japan during the first six waves of the
 429 epidemic. *Global Health & Medicine* 2022. DOI:10.35772/ghm.2022.01033.
- 430 17 Tsuzuki S, Miyazato Y, Terada M, Morioka S, Ohmagari N, Beutels P. Impact of
 431 long-COVID on health-related quality of life in Japanese COVID-19 patients.
 432 *Health and Quality of Life Outcomes* 2022; 20: 125.
- 433 18 Miyazato Y, Morioka S, Tsuzuki S, *et al.* Prolonged and Late-Onset Symptoms of
 434 Coronavirus Disease 2019. *Open Forum Infect Dis* 2020; 7: ofaa507.
- 43519 Ministry of Health, Labour and Welfare. Visualizing the data: information on436COVID-19infections.
- 437 https://covid19.mhlw.go.jp/extensions/public/en/index.html (accessed Feb 24,
 438 2022).
- 43920 National Institute of Population and Social Security Research. Population440Statistics.2020.
- 441 http://www.ipss.go.jp/syoushika/tohkei/Popular/Popular2014.asp?chap=5&title1=%

It is made available under a CC-BY-NC-ND 4.0 International license .

442 87X%81D%8E%80%96S%81E%8E%F5%96%BD (accessed Dec 20, 2020).

- 21 Tsuzuki S, Ohmagari N, Beutels P. The burden of isolation to the individual: a
 comparison between isolation for COVID-19 and for other influenza-like
 illnesses in Japan. *Epidemiology and Infection* 2022; 150: e5-undefined.
- 22 Glick HA, Miyazaki T, Hirano K, *et al.* One-Year Quality of Life Post-Pneumonia
 Diagnosis in Japanese Adults. *Clinical Infectious Diseases* 2021; 73: 283-90.
- 23 Thompson EJ, Williams DM, Walker AJ, et al. Long COVID burden and risk factors
 in 10 UK longitudinal studies and electronic health records. Nature
 Communications 2022; 13. DOI:10.1038/s41467-022-30836-0.
- 451 24 Wulf Hanson S, Abbafati C, Aerts JG, *et al.* Estimated Global Proportions of
 452 Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom
 453 Clusters Following Symptomatic COVID-19 in 2020 and 2021. *JAMA* 2022.
 454 DOI:10.1001/jama.2022.18931.
- 455 25 Augustovski F, Colantonio LD, Galante J, *et al.* Measuring the Benefits of
 456 Healthcare: DALYs and QALYs Does the Choice of Measure Matter? A Case Study
 457 of Two Preventive Interventions. *Int J Health Policy Manag* 2017; 7: 120-36.
- 26 Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the
 Economic Evaluation of Health Care Programmes, 4th edn. Oxford: Oxford
 University Press, 2015.
- 461 27 Tsuzuki S, Baguelin M, Pebody R, van Leeuwen E. Modelling the optimal target
 462 age group for seasonal influenza vaccination in Japan. *Vaccine* 2020; 38: 752463 62.
- 464 28 Tsuzuki S, Schwehm M, Eichner M. Simulation studies to assess the long-term
 465 effects of Japan's change from trivalent to quadrivalent influenza
 466 vaccination. Vaccine 2018; 36: 624-30.
- 467 29 R Core Team. R: A Language and Environment for Statistical Computing. 2018.
- 30 Shoji K, Akiyama T, Tsuzuki S, *et al.* Clinical characteristics of COVID-19 in
 hospitalized children during the Omicron variant predominant period. *J Infect Chemother* 2022; 28: 1531-5.

It is made available under a CC-BY-NC-ND 4.0 International license .

471 31 Shoji K, Akiyama T, Tsuzuki S, *et al.* Comparison of the clinical
472 characteristics and outcomes of COVID-19 in children before and after the
473 emergence of Delta variant of concern in Japan. *J Infect Chemother* 2022; 28:
474 591-4.

- 475 32 Mcdonald SA, Lagerweij GR, De Boer P, *et al.* The estimated disease burden of
 476 acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years.
 477 *European Journal of Epidemiology* 2022. DOI:10.1007/s10654-022-00895-0.
- 33 Wyper GMA, Fletcher E, Grant I, et al. Measuring disability-adjusted life
 years (DALYs) due to COVID-19 in Scotland, 2020. Archives of Public Health
 2022; 80. DOI:10.1186/s13690-022-00862-x.
- 481 34 Cuschieri S, Calleja N, Devleesschauwer B, Wyper GMA. Estimating the direct
 482 Covid-19 disability-adjusted life years impact on the Malta population for the
 483 first full year. *BMC Public Health* 2021; 21. DOI:10.1186/s12889-021-11893-4.
- 484 35 Rommel A, von der Lippe E, Pla D, *et al.* The COVID-19 Disease Burden in
 485 Germany in 2020. *Dtsch Arztebl International* 2021; 118: 145-51.
- 486 36 Pires SM, Redondo HG, Espenhain L, *et al.* Disability adjusted life years
 487 associated with COVID-19 in Denmark in the first year of the pandemic. *BMC*488 *Public Health* 2022; 22. DOI:10.1186/s12889-022-13694-9.
- 489 37 Zhao Y, Feng H, Qu J, Luo X, Ma W, Tian J. A systematic review of
 490 pharmacoeconomic guidelines. *Journal of Medical Economics* 2018; 21: 85-96.
- 491 38 Health Technology Assessment Toolkit. iDSI. 2017; published online Sept 7.
 492 https://www.idsihealth.org/htatoolkit/ (accessed Dec 8, 2022).
- 493 39 World Health Organization. WHO guide for standardization of economic
 494 evaluations of immunization programmes, 2nd ed.
 495 https://www.who.int/publications-detail-redirect/who-guide-for-
- 496 standardization-of-economic-evaluations-of-immunization-programmes-2nd-ed
- 497 (accessed Dec 8, 2022).
- 498 40 Eurosurveillance | Estimates of mortality attributable to COVID-19: a
 499 statistical model for monitoring COVID-19 and seasonal influenza, Denmark,

It is made available under a CC-BY-NC-ND 4.0 International license .

 500
 spring
 2020.
 https://www.eurosurveillance.org/content/10.2807/1560

 501
 7917. ES. 2021. 26. 8. 2001646 (accessed Feb 26, 2021).

- 41 Lipsitch M. Estimating case fatality rates of COVID-19. The Lancet Infectious
 Diseases 2020; 20: 775.
- 42 Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, *et al.* Infection fatality risk
 for SARS-CoV-2 in community dwelling population of Spain: nationwide
 seroepidemiological study. *BMJ* 2020; **371**: m4509.
- 43 Kawashima T, Nomura S, Tanoue Y, *et al.* Excess All-Cause Deaths during
 Coronavirus Disease Pandemic, Japan, January-May 2020 Volume 27, Number 3March 2021 Emerging Infectious Diseases journal CDC.
 DOI:10.3201/eid2703.203925.
- 44 Sugiyama A, Okada F, Abe K, *et al.* A longitudinal study of anti-SARS-CoV-2
 antibody seroprevalence in a random sample of the general population in
 Hiroshima in 2020. *Environmental Health and Preventive Medicine* 2022; 27: 3030.
- 515 45 World Health Organization. A clinical case definition of post COVID-19
 516 condition by a Delphi consensus, 6 October 2021. 2021; published online Oct 6.
 517 https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-

518 19_condition-Clinical_case_definition-2021.1 (accessed Sept 19, 2022).

46 Sandmann FG, Tessier E, Lacy J, et al. Long-Term Health-Related Quality of
Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With
Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Infection in England: Longitudinal Analysis and Cross-Sectional Comparison W. *Clinical Infectious Diseases* 2022. DOI:10.1093/cid/ciac151.

- 47 Malik P, Patel K, Pinto C, *et al.* Post-acute COVID-19 syndrome (PCS) and
 health-related quality of life (HRQoL)-A systematic review and meta-analysis. *J Med Virol* 2022; 94: 253-62.
- 48 Malinowska A, Muchlado M, Ślizień Z, *et al.* Post-COVID-19 Sydrome and Decrease
 in Health-Related Quality of Life in Kidney Transplant Recipients after SARSCOV-2 Infection-A Cohort Longitudinal Study from the North of Poland. *J Clin Med* 2021; 10: 5205.

It is made available under a CC-BY-NC-ND 4.0 International license .

49 Mckenzie L, Shoukat A, Wong KO, *et al.* Inferring the true number of SARS-CoV-2
infections in Japan. *Journal of Infection and Chemotherapy* 2022.
DOI:10.1016/j.jiac.2022.08.002.

- 50 Verelst F, Kuylen E, Beutels P. Indications for healthcare surge capacity in
 European countries facing an exponential increase in coronavirus disease
 (COVID-19) cases, March 2020. *Eurosurveillance* 2020; 25: 2000323.
- 51 McCabe R, Kont MD, Schmit N, *et al.* Modelling intensive care unit capacity
 under different epidemiological scenarios of the COVID-19 pandemic in three
 Western European countries. *International Journal of Epidemiology* 2021;
 published online April. DOI:10.1093/ije/dyab034.
- 52 Machida M, Wada K. Public health responses to COVID-19 in Japan. *Global Health & Medicine* 2022; 4: 78-82.
- 543 53 Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection.
 544 Nat Med 2022; 28: 1461-7.
- 545 54 Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness
 546 management in Japan. *BMC Public Health* 2020; 20: 568.

547

It is made available under a CC-BY-NC-ND 4.0 International license .

549 Figure legends

- 550 Figure 1. Progression pathway diagram of COVID-19 infection
- 551

552	Figure 2. Dail	v number of	confirmed	COVID-19	cases and hos	pitalisations
	A					

- 553 Wave 1; 01/01/2020-05/31/2020, Wave 2; 06/01/2020-10/31/2020, Wave 3; 11/01/2020-
- 554 03/31/2021, Wave 4; 4/1/2021-6/30/2021, Wave 5; 7/1/2021-12/31/2021
- 555 Bars represent the daily number of confirmed cases. The black line represents the
- number of cases requiring hospitalization. Vertical lines represent the delimitation of
- 557 five epidemic waves.
- 558

559 Figure 3. Comparison of QALYs lost per 100,000 population in each epidemic wave

- 560 Wave 1; 01/01/2020-05/31/2020, Wave 2; 06/01/2020-10/31/2020, Wave 3; 11/01/2020-
- 561 03/31/2021, Wave 4; 4/1/2021-6/30/2021, Wave 5; 7/1/2021-12/31/2021
- 562 Light grey bars represent QALYs lost due to morbidity and dark grey bars represent
- 563 QALYs lost due to mortality.
- 564 QALYs; Quality-adjusted life years
- 565 Panel a: Disease burden in total population
- 566 Panel b: Disease burden in population under 40

It is made available under a CC-BY-NC-ND 4.0 International license .

- 567 Panel c: Disease burden in population between age 40 and 69
- 568 Panel d: Disease burden in population 70 and over

569

570	Figure 4.	Breakdown of	disease	burden	by clinical	manifestation	of COVID-19
-----	-----------	--------------	---------	--------	-------------	---------------	-------------

- 571 QALYs; Quality-adjusted life years
- 572 *Count without quality adjustment (i.e., assuming life years lost due to premature mortality
- 573 would have been lived in perfect health).
- 574
- 575 **Figure 5.** Linear regression coefficient of each parameter included in the probabilistic
- 576 sensitivity analysis
- 577 X axis represents coefficient value of each parameter.









